Search for: "Par Pharmaceutical"
Results 161 - 180
of 303
Sorted by Relevance
|
Sort by Date
17 Oct 2010, 9:55 am
Her expertise is working with employers to reduce workers compensation costs, and her clients include airlines, healthcare, printing/publishing, pharmaceuticals, retail, hospitality and manufacturing. [read post]
5 Mar 2020, 5:15 am
It is certainly true that developing new pharmaceuticals requires massive investments. [read post]
5 May 2010, 4:46 am
Cyclacel Pharmaceuticals Inc. [read post]
27 Jul 2010, 7:18 pm
Efforts are under way in the courts and congress to reign in patent settlement agreements under which the brand-name drug firm pays its potential generic competitor to abandon a patent challenge and delay entering the market.The agency is currently pursuing two major pay-for-delay cases: one against Solvay Pharmaceuticals (owned by Abbott Laboratories) and generic manufacturers (Watson Pharmaceuticals, Par Pharmaceutical, and Paddock Laboratories) regarding… [read post]
23 Jun 2010, 5:00 am
In addition, however, it would be both unimportant to investors ("Any reasonably sophisticated investor buying shares in a pharmaceutical company must realize that consumers will, from time to time, experience adverse events after using the company’s product. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
10 Jun 2010, 3:58 am
Par Pharmaceutical, Inc. [read post]
25 Apr 2012, 1:56 pm
The FTC brought the case in 2009 against Solvay Pharmaceuticals and generic manufacturers Watson Pharmaceuticals, Par Pharmaceutical, and Paddock Laboratories over a “pay for delay” or “reverse payment” patent infringement settlement agreement related to patents for AndroGel—a testosterone replacement drug often used by men whose bodies do not produce normal levels of testosterone. [read post]
19 Aug 2014, 6:58 am
There are also plans to create a central U.S. office dedicated to pharmaceutical quality. [read post]
24 Jun 2010, 5:00 am
To the extent that pharmaceutical companies had a practice of disclosing every adverse report on their web site, for example, it is unlikely that analysts would object. [read post]
10 Oct 2013, 8:42 am
Par Pharmaceutical Companies Inc. ($45 million) Par Pharmaceutical Companies, Inc., one of the top five U.S. generic pharmaceutical companies, pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
15 Jun 2011, 4:56 am
Par Pharmaceutical, Inc. [read post]
13 Jul 2011, 3:04 am
(The SPC Blog) Doha+10: On November 14, 2011, a meeting at WIPO in Geneva to discuss the Doha Declaration (KEI) Docs at BIO: Session on IP challenges for personalised medicine (Patent Docs) France to reform its pharmaceutical regulatory system… with possible global implications! [read post]
Pre-Post Podcast Series Preview: Litigation and E-Discovery Strategies: Meet & Confer Best Practices
4 Jan 2010, 3:48 am
., Senior Director, Legal, Compliance | Par Pharmaceutical, Inc.Moderator:Virginia P. [read post]
26 Jun 2008, 5:00 pm
Ingersoll (not a typo, the proposal has been approved by shareholders twice at this company), Motorola, Verizon Communications, Blockbuster, Activision, Clear Channel Communications, and Par Pharmaceutical. [read post]
10 May 2007, 11:17 am
Bottom Row: Tom Haughey, general counsel, Par Pharmaceutical; Kenneth Steinthal, Weil Gotshal; Myles Berman, Top Gun DUI; Thomas McGraw, Gibson Dunn; John Rodney, Thorp Reed; Richard Silverman, Hogan & Hartson. [read post]
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs) Products Cepham… [read post]
16 Aug 2011, 11:35 pm
PTO does not appear to invalidate very many gene patent method claims (Holman’s Biotech IP Blog) US: Machine-or-transformation test after Myriad: Implications to the prosecution of process claims (Patent Law Practice Center) US: Unsuccessful Qui Tam plaintiff asserting false marking claim not immune from costs award: Promote Innovation v Roche Diagnostics (Docket Report) US: FDA releases two medical device draft guidances (FDA Law Blog) US: BIO: Unleashing the promise of biotechnology (pt.4)… [read post]
7 May 2012, 5:51 am
In order to provide article 5 par. 3 with real effectiveness, the Court conducts a systematic and coherent interpretation of articles 5 par.3, 5 par. 1, 6 par. 1, 9 par. 1 and of the recitals 17 and 18 of the Directive. [read post]
